Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia

Connecticut Medicine

Volumn 68, Issue 9, 2004, Pages 547-549

  Chung, Keun Sam ^a   Carson, Shawn ^b   Glassman, David ^a   Vadivelu, Nalini ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDIAZEPOXIDE; HALOPERIDOL; HYDROMORPHONE; METHADONE;

ADULT; ARTICLE; BLADDER CARCINOMA; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG INDUCED DISEASE; HUMAN; HYPERALGESIA; MALE; NEUROTOXICITY; PAIN; PATIENT CONTROLLED ANALGESIA; PROSTATE CARCINOMA;

HUMANS; HYDROMORPHONE; HYPERALGESIA; MALE; METHADONE; MIDDLE AGED; NARCOTICS; NEUROTOXICITY SYNDROMES; PAIN;

EID: 4644289902     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sjogren P, Jensen NH, Jensen TS: Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59(2):313-6.
2. Babul N, Darke AC: Putative role of hydromorphone metabolites in myoclonus. Pain 1992; 51(2):260-1.
3. Eisele JH, Jr., Grigsby EJ, Dea G: Clonazepam treatment of myoclonic contractions associated with high-dose opioids: Case report. Pain 1992; 49(2):231-2.
4. Vigano A, Fan D, Bruera E: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996; 67(1): 115-9.
5. Mercadante S: Dantrolene treatment of opioid-induced myoclonus. Anesth Analg 1995; 81(6):1307-8.
6. Ossipov MH, Lai J, Vanderah TW, Porreca F: Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance. Life Sci 2003; 73(6):783-800.
7. Gardell LR, Wang R, Burgess SE, et al: Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22(15):6747-55.
8. Mao J: Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain 2002; 100(3):213-7.
9. Bartlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci 1994; 54(10):687-94.
10. Smith MT, Wright AW, Williams BE, et al: Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg 1999; 88(1):109-16.
11. Ossipov MH, Lai J, Vanderah TW, Porreca F: Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance. Life Sciences 2003; 73(6):783-800.
12. Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14(4):2301-12.